We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex (VRTX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
In its upcoming report, Vertex Pharmaceuticals (VRTX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $4.13 per share, reflecting an increase of 1.2% compared to the same period last year. Revenues are forecasted to be $2.68 billion, representing a year-over-year increase of 7.8%.
The consensus EPS estimate for the quarter has been revised 1.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Vertex metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Revenues by Product- Trikafta/Kaftrio' will reach $2.49 billion. The estimate suggests a change of +9.3% year over year.
Analysts forecast 'Geographic Revenues- United States' to reach $1.64 billion. The estimate indicates a year-over-year change of +5.6%.
Analysts' assessment points toward 'Geographic Revenues- Outside of the United States' reaching $1.04 billion. The estimate points to a change of +11.9% from the year-ago quarter.
Over the past month, shares of Vertex have returned +0.1% versus the Zacks S&P 500 composite's +1.8% change. Currently, VRTX carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex (VRTX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
In its upcoming report, Vertex Pharmaceuticals (VRTX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $4.13 per share, reflecting an increase of 1.2% compared to the same period last year. Revenues are forecasted to be $2.68 billion, representing a year-over-year increase of 7.8%.
The consensus EPS estimate for the quarter has been revised 1.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Vertex metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Revenues by Product- Trikafta/Kaftrio' will reach $2.49 billion. The estimate suggests a change of +9.3% year over year.
Analysts forecast 'Geographic Revenues- United States' to reach $1.64 billion. The estimate indicates a year-over-year change of +5.6%.
Analysts' assessment points toward 'Geographic Revenues- Outside of the United States' reaching $1.04 billion. The estimate points to a change of +11.9% from the year-ago quarter.
View all Key Company Metrics for Vertex here>>>
Over the past month, shares of Vertex have returned +0.1% versus the Zacks S&P 500 composite's +1.8% change. Currently, VRTX carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>